<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002696</url>
  </required_header>
  <id_info>
    <org_study_id>GOCS-08-BR-95-III</org_study_id>
    <secondary_id>CDR0000064471</secondary_id>
    <secondary_id>NCI-F95-0036</secondary_id>
    <nct_id>NCT00002696</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Women With Stage III Breast Cancer</brief_title>
  <official_title>MULTIMODALITY TREATMENT STRATEGY FOR STAGE III BREAST CANCER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Oncologico Cooperativo del Sur</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug may kill more tumor cells.

      PURPOSE: Randomized phase III trial to compare cyclophosphamide, doxorubicin, and
      fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in treating women with
      stage III breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the response in women with stage III breast cancer treated with neoadjuvant
           fluorouracil, doxorubicin, and cyclophosphamide (FAC) vs cyclophosphamide, methotrexate,
           and fluorouracil (CMF).

        -  Compare the rates of conservative surgical resectability and locoregional control in
           patients treated with these neoadjuvant therapy regimens.

        -  Compare the disease-free and overall survival of patients treated with these regimens.

        -  Compare the toxic effects of these regimens in these patients.

        -  Compare the compliance of patients treated with these regimens.

        -  Assess the cosmetic results in patients treated with conservative surgery.

        -  Compare the quality of life of patients treated with these regimens.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
      participating center.

        -  Arm I: Patients receive fluorouracil (5-FU) IV on days 1 and 8 and doxorubicin IV and
           cyclophosphamide (CTX) IV on day 1 (FAC). Treatment continues every 3 weeks for 3
           courses in the absence of disease progression.

        -  Arm II: Patients receive CTX IV, methotrexate IV, and 5-FU IV on days 1 and 8 (CMF).
           Treatment continues every 4 weeks for 3 courses in the absence of disease progression.

      Patients on both arms with resectable disease after the third course of chemotherapy undergo
      quadrantectomy with axillary node dissection (preferred) or modified radical mastectomy,
      followed by 6 additional courses of chemotherapy on the arm to which they were randomized
      initially. Those patients without distant metastasis undergo locoregional radiotherapy
      beginning concurrently with the initiation of postoperative chemotherapy. Patients on both
      arms with unresectable disease after the initial 3 courses of chemotherapy undergo
      locoregional radiotherapy and then surgical resection (if feasible).

      Quality of life is assessed at baseline and then monthly thereafter.

      Patients are followed every 3-4 months for 2 years, every 4-6 months for 3 years, and then
      annually thereafter.

      PROJECTED ACCRUAL: Not specified
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <start_date>October 1995</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAF regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CMF regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed stage III breast cancer

          -  Measurable disease

          -  No inflammatory breast cancer

          -  No synchronous bilateral breast cancer

          -  Hormone receptor status:

               -  Not specified

        PATIENT CHARACTERISTICS:

        Age:

          -  21 to 75

        Sex:

          -  Female

        Menopausal status:

          -  Not specified

        Performance status:

          -  ECOG 0-1 OR

          -  Zubrod 0-1

        Life expectancy:

          -  More than 12 weeks

        Hematopoietic:

          -  WBC greater than 4,000/mm^3

          -  Platelet count greater than 100,000/mm^3

        Hepatic:

          -  Bilirubin less than 1.25 times upper limit of normal (ULN)

          -  AST less than 1.25 times ULN

        Renal:

          -  Creatinine clearance greater than 70 mL/min

        Cardiovascular:

          -  No angina pectoris

          -  No significant arrhythmia requiring therapy

          -  No bilateral bundle branch block

          -  No congestive heart failure

          -  No myocardial infarction

        Other:

          -  No medical or psychiatric disease that would preclude study therapy

          -  No other malignancy except adequately treated nonmelanomatous skin cancer or carcinoma
             in situ of the cervix

          -  Not pregnant

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Not specified

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  No prior radiotherapy

        Surgery:

          -  No prior surgery except incisional biopsy or fine-needle aspiration

        Other:

          -  No prior systemic therapy

          -  No concurrent caffeine or alcohol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernardo A. Leone, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Unidad Oncologica Del Neuquen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Policlinica Privada Instituto De Medicina Nuclear</name>
      <address>
        <city>Bahia Blanca</city>
        <state>Buenos Aires</state>
        <zip>8000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorio Oncologico Privado</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>7600</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro De Oncologia y Terapia Radiante</name>
      <address>
        <city>Santa Rosa</city>
        <state>La Pampa</state>
        <zip>6300</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad Oncologica Del Comahue</name>
      <address>
        <city>Neuquen</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorio Oncologico Privado</name>
      <address>
        <city>Rio Gallegos</city>
        <zip>9400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Del Litoral</name>
      <address>
        <city>Santa Fe</city>
        <zip>3000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Tres Arroyos</name>
      <address>
        <city>Tres Arroyos</city>
        <zip>7500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 1, 2013</last_update_submitted>
  <last_update_submitted_qc>August 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2013</last_update_posted>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

